The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 13, 2025

Filed:

Aug. 15, 2018
Applicant:

Elanco Us Inc., Greenfield, IN (US);

Inventors:

Hangjun Zhan, Foster City, CA (US);

Lam Nguyen, Union City, CA (US);

Yongzhong Li, Rockville, MD (US);

Fawn Qian, Burlingame, CA (US);

Shyr Jiann Li, Millbrae, CA (US);

Assignee:

Eianco US inc., Greenfield, IN (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); A61K 9/00 (2006.01); A61K 39/395 (2006.01); A61P 3/04 (2006.01); C07K 14/605 (2006.01); A61K 38/00 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
C07K 16/283 (2013.01); A61K 9/0019 (2013.01); A61P 3/04 (2018.01); C07K 14/605 (2013.01); A61K 38/00 (2013.01); A61K 39/395 (2013.01); A61K 45/06 (2013.01); C07K 2317/31 (2013.01); C07K 2317/53 (2013.01); C07K 2317/71 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01); C07K 2319/30 (2013.01);
Abstract

Provided are various embodiments relating to variant IgG Fc polypeptides of companion animals having increased Protein A binding for ease of purification, decreased C1q binding for reduced complement-mediated immune responses, decreased CD16 binding (e.g., for reduced antibody-dependent cellular cytotoxicity (ADCC) induction, increased stability, and/or the ability to form heterodimeric proteins. In addition, various embodiments relating to antibodies and fusion proteins comprising such variant IgG Fc polypeptides are provided. Also provided are various embodiments relating to contiguous polypeptides comprising one or more variant GLP1 polypeptide(s) having improved serum half-life. Further provided are various embodiments relating to contiguous polypeptides or heterodimeric polypeptides comprising a GLP1 polypeptide and a glucagon polypeptide as a dual GLP1 receptor and glucagon receptor agonist. In various embodiments, such polypeptides may be used to treat, for example, diabetes, obesity, or related indications, in companion animals, such as canines, felines, and equines.


Find Patent Forward Citations

Loading…